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 First described following 1976 outbreak at American 
Legion convention in Philadelphia
 221 cases of Legionnaires’                                                          
disease with 34 deaths
 Cooling system                                                                                                        




 Atypical gram-negative bacillus
 Intracellular parasite of free-living                            
protozoa primarily found in freshwater                  
environments 
 There are 52 species and 70 serogroups of Legionella
 22 species associated with human disease
 Legionella pneumophila accounts for  80-90% of all 
cases
 Molecular subtyping of L. pneumophila
 Monoclonal antibody typing (MAb typing) 
 Sequence-based typing (SBT)
Legionella is found naturally in fresh water
BUT natural environments (e.g., lakes, rivers) do NOT 
have sufficient quantities of Legionella to cause 
transmission
Amplification
 Temperature 25ºC - 42ºC  (77ºF-108ºF)
 Stagnation
 Scale and sediments
 Biofilms
 Presence of amoebae
 Natural rubbers, wood and some plastics support 
growth, copper inhibits growth
Temperature Range for Legionella
Transmission via Aerosolized Water
Legionellosis 
(Legionnaires’ disease and Pontiac fever)
LD Pontiac fever
Clinical Features Pneumonia Flu-like illness
Hospitalization Common Uncommon
Treatment Antibiotics None
Case Fatality Rate 5-40% 0%
Attack Rate <5% >85%




Incubation Period 2-10 days 1-3 days
Isolation of Organism Possible Virtually never




Clinical Features of LD
 Incubation period is 2-10 days (most often 5-6 days)
 Difficult to distinguish from other causes of pneumonia
 Initial symptoms include anorexia, malaise, myalgia, 
headache
 Within 24 hrs, rapidly rising fever 102-105°F
 Nonproductive cough, abdominal pain, nausea, 
vomiting, and diarrhea are common
 Chest radiograph: patchy infiltrates or focal areas of 
consolidation which may progress to bilateral 
involvement and respiratory failure









Culture • Clinical & environmental 
isolates can be compared




• Slow (>5 days to grow)




• 60-80% sensitive, >99% 
specific (for Lp1 only)
• Rapid (same day)
• Can only  detect L. pneumophila
serogroup 1 (Lp1) antigen
• Limited utility when compared to 
environmental isolates
Serology • Unaffected by antibiotic 
treatment
• 70-80% sensitive, >90% 
specific
• MUST have paired sera
• 5-10% of population has titer 
>1:256





 Number one cause of atypical community-acquired 
pneumonia among patients who are admitted to ICU
 8,000-18,000 hospitalizations in the U.S. each year
 Inpatient cost estimates total $92-582 million per year
 During 2005-2006, 50% of all drinking water outbreaks 
nationwide were caused by Legionella
 10-20% are outbreak-associated
 20% are travel-associated
 Incidence is increasing 
National Incidence of Legionellosis, 1998-2009*































 Training and Education
 Outbreak Coordination and Response
 Clinical and Environmental Laboratory Diagnostics




 Legionellosis is one of ~67 nationally notifiable
infectious diseases reported to the National Notifiable
Diseases Surveillance System (NNDSS)
 NNDSS collects basic count data, sex, and age
 RDB maintains a supplemental surveillance system, 
which collects travel history, hospitalizations/LTCF 
exposures, disease (LD vs. PF), method of lab 
confirmation,  and case status
 Additionally, outbreaks are reported through the 
National Outbreak Reporting System (NORS) to the 
Waterborne Disease Prevention Branch (WBDPB)
 National case definition is defined by CDC & CSTE
One Year Active Surveillance Pilot
 Volunteer EIP/ABCs sites will pilot lab-based active 
surveillance for legionellosis in 2010
 Other proposed activities:
 Lab survey
 One-time chart audit of hospital discharges with a legionellosis 
diagnosis
 Retrospective review of cases to improve understanding of 
disease trends and use of diagnostics
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